Ziirsen replaces Damon Rasheed who has stepped into an executive director role to leverage his expertise in the Artificial Intelligence space.
The new appointment is an experienced non-executive director and CFO of ASX-listed companies, having served as non-executive director and chair of Respiri Limited (ASX:RSH), an eHealth SaaS company supporting respiratory health management.
His executive career includes senior finance leadership roles with major ASX-listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited.
Financial and commercial experience
Chairman Julian Chick said: “We are delighted to welcome Mark to the board, as he brings a wealth of financial and commercial experience in the health sector.
“Mark’s expertise and networks will complement the Opyl leadership team, particularly as we extend our footprint.”
Ziirsen commenced his career with EY in business advisory, tax and management consulting.
Most recently, he was chief financial officer (CFO) and company secretary for Wiseway Group Ltd (ASX:WWG) where he successfully led the company through an IPO, listing on ASX.
Prior to that, he was CFO of listed global medtech company Anteris Technologies Ltd (ASX:AVR) and before that, director of finance and IT for Asia Pacific at hearing implant maker Cochlear Limited (ASX:COH).
He has a strong track record in delivering growth and operational improvement across multiple industry sectors (medtech/health, technology, consumer) and geographies, having worked extensively in Asia for more than 25 years.
His strong finance and operations credentials are complemented by extensive corporate finance, governance, risk management, strategy, M&A and investor relations skills.
Much of Ziirsen’s work has involved guiding high growth and early-stage companies.
“Great excitement and determination”
In accepting the board position, he said: “Opyl has a significant opportunity to evolve and further commercialise its technology platforms and I understand the capability and global opportunity for the company.
“It is with great excitement and determination that I join the Opyl board to assist in making a significant contribution to the ongoing growth of the business.”
With the recent priority focus on accelerating the development of the Opyl Clinical Trial Predictor Tool, Damon is taking a more active role in supporting the advancement of technologies within the company, leveraging his expertise in AI.